TNFSF10 and prostate carcinoma: Oishi et al. and Kim et al. also reported a role for DR5 in apigenin-mediated TRAIL sensitization in prostate cancer cells (DU145 and LNCaP) and hepatocellular carcinoma (HCC) cells (HepG2), respectively [43,44].